• Molecular NameBacitracin
  • SynonymNA
  • Weight1422.72
  • Drugbank_IDDB00626
  • ACS_NO1405-87-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)N/A
  • pkaN/A
  • LogD (pH=7, predicted)N/A
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)N/A
  • LogSw (predicted, AB/LogsW2.0)N/A
  • Sw (mg/ml) (predicted, ACD/Labs)N/A
  • No.of HBond DonorsN/A
  • No.of HBond AcceptorsN/A
  • No.of Rotatable BondsN/A
  • TPSAN/A
  • StatusFDA approved
  • AdministrationTopical, intramuscular
  • PharmacologyA mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy, isolation of which was first reported in 1945.
  • Absorption_valueN/A
  • Absorption (description)Absorption of bacitracin following intramuscular injection is rapid and complete. Absorption from the gastrointestinal tract following oral administration is not appreciable. Absorption following topical application is negligible.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityOral, mouse: LD50 = >3750 mg/kg.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A